You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. POC Blood Coagulopathy Monitor

    SBC: CFD RESEARCH CORPORATION            Topic: DHA19A001

    Traumatic injuries account for 30% of all life years lost in the US and is the leading cause of death for people under 46 years of age. Uncontrolled bleeding or hemorrhage constitute 30-40% of trauma related deaths and are considered to be a major cause o

    STTR Phase I 2019 Department of DefenseDefense Health Agency
  2. Multi-Functional Nanotube-Based Sensor Array for Detecting Blood Coagulation Defects

    SBC: INNOSENSE CORPORATION            Topic: DHA19A001

    Defense Health Agency (DHA) is seeking a multi-functional diagnostic to determine blood coagulopathy in real time at point-of-care (POC). Blood coagulopathy, resulting in uncontrolled bleeding, is implicated in 80% of operating room deaths and 50% of trau

    STTR Phase I 2019 Department of DefenseDefense Health Agency
  3. Cervical Spine Health Improvement Products

    SBC: SWITCHBOX INC            Topic: DHA18B001

    Most standard-of-care tools and techniques for evaluating neck disorders are subjective, unreliable, and do not provide actionable information for providers, payers, and organizations to deliver efficient and effective care. This lack of objective neck he

    STTR Phase I 2019 Department of DefenseDefense Health Agency
  4. Novel Circulating RNA-based Markers as Diagnostic Biomarkers of Infectious Diseases

    SBC: CFD RESEARCH CORPORATION            Topic: CBD18A001

    In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens,whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial andalphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable and ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  5. Marburg Virus Prophylactic Medical Countermeasure

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: CBD18A002

    There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  6. Virus-Like Particle Based pan-Marburgvirus Vaccine

    SBC: LUNA INNOVATIONS INCORPORATED            Topic: CBD18A002

    Marburg virus (MARV) is a filamentous enveloped non-segmented negative sense RNA virus. This viruse is considered to be extremelydangerous with case fatality rates as high as 88-90%. Extensive efforts have gone towards effective vaccines for MARV prevention, however,none have been successfully established as licensed vaccines. Glycoprotein (GP) is the only surface protein of MARV. There are substa ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  7. Marburg Virus Prophylactic Medical Countermeasure

    SBC: Flow Pharma, Inc.            Topic: CBD18A002

    Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by i ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  8. Functionalized, Therapeutic-Loaded Liposomes for the Acute Treatment of TBI

    SBC: LUNA INNOVATIONS INCORPORATED            Topic: DHA18A001

    Traumatic brain injury is a common problem in both the military and civilian communities, but current treatment protocols are focused on managing symptoms and fail to prevent significant long-term repercussions. In the proposed program, Luna will demonstrate the feasibility of a liposome-based therapeutic delivery system capable of delivering hydrophilic and hydrophobic therapeutics to the traumat ...

    STTR Phase I 2018 Department of DefenseDefense Health Agency
  9. Brain Targeting Nanoparticle for Drug Delivery in Traumatic Brain Injury

    SBC: WEINBERG MEDICAL PHYSICS, INC.            Topic: DHA18A001

    There is an urgent need to bypass or cross the blood brain barrier (BBB) to deliver drugs for TBI treatment. This project aims to develop targted intranasally delivered, magnetically propulsed, and targted nanoparticles for traumatic brain injury (TBI). In Phase I, we will demonstrate the design, fabrication, and in vitro characterization of proposed drug laden magnetic nanoparticles as well as co ...

    STTR Phase I 2018 Department of DefenseDefense Health Agency
  10. Probabilistic Pharmacokinetic Models for Diagnosis, Prognosis, and Personalized Treatment

    SBC: BARRON ASSOCIATES, INC.            Topic: DHA17B003

    Clinicians have recognized that the nature of diseases can be highly individual resulting in different patterns of onset and progression. In turn, the response of an individual to drugs is also unique and governed by a variety of factors. Pharmacokinetic models represent the movement of a drug through the body, and personalized pharmacokinetic models aim to capture the unique responses of specific ...

    STTR Phase I 2018 Department of DefenseDefense Health Agency
US Flag An Official Website of the United States Government